AMENDMENT

A. Claims

The listing of claims below will replace all prior versions, and listings, of claims in the application. Please amend claims 1 and 21 as follows:

Claim 1 (currently amended) A radiopharmaceutical macroaggregate composition for the treatment of abnormal tissue comprising particles having a minimum size of one micron, wherein the particles comprise a coprecipitate of a metal and one or more radioactive isotopes, and have sufficient radioactivity for locoregional ablation of cells in the abnormal tissue.

Claim 2 (original) The composition of claim 1, wherein the radiopharmaceutical macroaggregate composition is paramagnetic.

Claim 3 (withdrawn) The composition of claim 1, wherein the radiopharmaceutical macroaggregate composition is nonparamagnetic.

Claim 4 (original) The composition of claim 1, wherein the metal is iron or gadolinium.

Claim 5 (withdrawn) The composition of claim 1, wherein the metal is calcium.

Claim 6 (original) The composition of claim 1, wherein the one or more radioactive isotopes are selected from the group consisting of Gallium-67 (^{67}Ga), Yttrium-90 (^{90}Y), Yttrium-86 (^{86}Y), Gallium-68 (^{68}Ga), Thallium-201 (^{201}Tl), Strontium-89 (^{89}Sr), Indium-111 (^{111}In), Iodine-131 (^{131}I), Samarium-153 (^{153}Sm), Technetium-99m (^{99m}Tc), Rhenium-186 (^{186}Re), Rhenium-188 (^{188}Re), Copper-62 (^{62}Cu), and Copper-64 (^{64}Cu).

Claim 7 (original) The composition of claim 1, wherein the radiopharmaceutical macroaggregate composition comprises particulates or microspheres.

Claim 8 (original) The composition of claim 7, wherein the particulates or microspheres comprise glass.

Claim 9 (withdrawn) The composition of claim 7, wherein the particulates or microspheres comprise ceramic.

Claim 10 (original) The composition of claim 1, wherein the one or more radioactive isotopes emit beta radiations or positrons.

Claim 11 (original) The composition of claim 1, wherein the particles comprise a metal and one radioactive isotope.

Claim 12 (original) The composition of claim 11, wherein the radioactive isotope is a cation.

Claim 13 (withdrawn) The composition of claim 11, wherein the radioactive isotope is an anion.

Claim 14 (original) The composition of claim 1, wherein the particles comprise a metal and two radioactive isotopes.

Claim 15 (original) The composition of claim 14, wherein one or both of the radioactive isotope are cations.

Claim 16 (withdrawn) The composition of claim 14, wherein one or both of the radioactive isotope are anions.

Claim 17 (withdrawn) The composition of claim 14, wherein one of the radioactive isotopes is Holmium-166 (^{166}Ho).

Claim 18 (original) The composition of claim 1, wherein the particles further comprise Phytate.

Claim 19 (original) The composition of claim 10, wherein the particles further comprise Phytate.

Claim 20 (original) The composition of claim 14, wherein the particles further comprise Phytate.

Claim 21 (currently amended) The composition of claim 1, wherein the ratio of radioactive isotopes to metal is about ~~10^6:1~~ 1: 10^6.

Claim 22 (original) The composition of claim 1, wherein the particles are biodegradable.

Claim 23 (original) The composition of claim 1, wherein the size of the particles is from about 5 to about 50 microns.

Claims 24-44 (canceled).

Claim 45 (withdrawn) A radiopharmaceutical macroaggregate composition for the treatment of abnormal tissue comprising particles having a minimum size of one micron, wherein the particles comprise a metal and one or more radioactive isotopes, and have sufficient radioactivity for locoregional ablation of cells in the abnormal, produced by a process comprising the steps of:

(a) mixing one or more radioactive isotopes with a metal chloride;

(b) adding an alkaline to the mixture of part a to precipitate the radioactive isotopes with the metal to form the particles;

(c) separating the precipitated particles from any remaining soluble radioactive isotopes from the particles; and

(d) isolating the radioactive particles.

Claim 46 (withdrawn) The process of claim 45, wherein the metal chloride is selected from the group consisting of ferric chloride ($FeCl_3$), calcium chloride ($CaCl_2$), and gandolinium chloride ($GdCl_3$).

Claim 47 (withdrawn) The process of claim 45, wherein the alkaline is sodium hydroxide or ammonium hydroxide.

Claim 48 (withdrawn) A radiopharmaceutical macroaggregate composition for the treatment of abnormal tissue comprising particles having a minimum size of one micron, wherein the particles comprise a metal and one or more radioactive isotopes, and have sufficient radioactivity for locoregional ablation of cells in the abnormal, produced by a process comprising the steps of:

(a) adding an alkaline to a metal chloride to form a precipitate;

(b) mixing one or more radioactive isotopes with the precipitate of part (a) to allow the radioactive isotopes to adsorb to the precipitate and generate a radioactive precipitate;

(c) separating the radioactive precipitate of part (b) from any remaining soluble radioactive isotopes; and

(d) isolating the radioactive precipitate.

Claim 49 (withdrawn) The process of claim 48, wherein the metal chloride is selected from the group consisting of ferric chloride ($FeCl_3$), calcium chloride ($CaCl_2$), and gandolinium chloride ($GdCl_3$).

Claim 50 (withdrawn) The process of claim 48, wherein the alkaline is sodium hydroxide or ammonium hydroxide.

Claim 51 (withdrawn) The process of claim 48, wherein the radioactive precipitate of part (b) is separated from any remaining soluble radioactive isotopes by centrifugation.

Claim 52 (canceled).